NEO-201

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNEO-201
Drug Alias Nameh16C3-Abbh16C3NEO-201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsCarcinoembryonic antigen related cell adhesion molecule 6 inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 5Carcinoembryonic antigen related cell adhesion molecule 6
Therapy Area/IndicationsUterine Cervical NeoplasmsUterine NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrecision Biologics IncNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesPrecision Biologics Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsUterine NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A